JP6074142B2 - 医薬化合物の結晶化 - Google Patents

医薬化合物の結晶化 Download PDF

Info

Publication number
JP6074142B2
JP6074142B2 JP2011552157A JP2011552157A JP6074142B2 JP 6074142 B2 JP6074142 B2 JP 6074142B2 JP 2011552157 A JP2011552157 A JP 2011552157A JP 2011552157 A JP2011552157 A JP 2011552157A JP 6074142 B2 JP6074142 B2 JP 6074142B2
Authority
JP
Japan
Prior art keywords
tadalafil
peaks
molecular complex
crystalline molecular
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011552157A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012519178A5 (enExample
JP2012519178A (ja
Inventor
ハンナ，マーゼン
シャン，ニン
チェイニー，ミランダ，エル
ワイナ，デーヴィッド，アール．
Original Assignee
タール ファーマシューティカルズ，インコーポレイテッド
タール ファーマシューティカルズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タール ファーマシューティカルズ，インコーポレイテッド, タール ファーマシューティカルズ，インコーポレイテッド filed Critical タール ファーマシューティカルズ，インコーポレイテッド
Publication of JP2012519178A publication Critical patent/JP2012519178A/ja
Publication of JP2012519178A5 publication Critical patent/JP2012519178A5/ja
Application granted granted Critical
Publication of JP6074142B2 publication Critical patent/JP6074142B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2011552157A 2009-02-26 2010-02-25 医薬化合物の結晶化 Expired - Fee Related JP6074142B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20862409P 2009-02-26 2009-02-26
US61/208,624 2009-02-26
PCT/US2010/025421 WO2010099323A1 (en) 2009-02-26 2010-02-25 Crystalization of pharmaceutical compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015021058A Division JP2015134774A (ja) 2009-02-26 2015-02-05 医薬化合物の結晶化

Publications (3)

Publication Number Publication Date
JP2012519178A JP2012519178A (ja) 2012-08-23
JP2012519178A5 JP2012519178A5 (enExample) 2016-12-15
JP6074142B2 true JP6074142B2 (ja) 2017-02-01

Family

ID=42665904

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011552157A Expired - Fee Related JP6074142B2 (ja) 2009-02-26 2010-02-25 医薬化合物の結晶化
JP2015021058A Pending JP2015134774A (ja) 2009-02-26 2015-02-05 医薬化合物の結晶化

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015021058A Pending JP2015134774A (ja) 2009-02-26 2015-02-05 医薬化合物の結晶化

Country Status (4)

Country Link
US (2) US8586587B2 (enExample)
EP (1) EP2400848A4 (enExample)
JP (2) JP6074142B2 (enExample)
WO (1) WO2010099323A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6074142B2 (ja) * 2009-02-26 2017-02-01 タール ファーマシューティカルズ，インコーポレイテッド 医薬化合物の結晶化
WO2013109223A1 (en) 2012-01-18 2013-07-25 Mahmut Bilgic Particulate formulations of tadalafil in effervescent form
MX357741B (es) 2012-07-06 2018-07-23 Laboratorios Senosiain S A De C V Star Nuevas formas sólidas de inhibidores de fosfodiesterasa tipo 5.
CN104086546B (zh) * 2014-07-14 2016-08-17 福建广生堂药业股份有限公司 他达拉非的药用酸盐及其制备方法
EA035390B1 (ru) 2014-07-23 2020-06-05 КРКА, д.д., НОВО МЕСТО Совместный осадок тадалафила с фармацевтически приемлемыми эксципиентами, содержащая его фармацевтическая композиция и способ их получения
CN105481860B (zh) * 2015-12-31 2018-03-02 山西普德药业有限公司 一种他达拉非i型晶体的精制工艺
CN110940755A (zh) * 2019-12-18 2020-03-31 山西省食品药品检验所(山西省药品包装材料监测中心) 一种食品中4种他达拉非类物质的检测方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4490371A (en) * 1983-02-16 1984-12-25 Syntex (U.S.A.) Inc. N,N-Disubstituted-(2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-B]quinazolinyl)oxyalkylamides
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US6943166B1 (en) 1999-04-30 2005-09-13 Lilly Icos Llc. Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
NZ516616A (en) 1999-08-03 2003-07-25 Lilly Icos Llc Beta-carboline pharmaceutical compositions
US6821975B1 (en) 1999-08-03 2004-11-23 Lilly Icos Llc Beta-carboline drug products
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
WO2003074474A2 (en) 2002-03-01 2003-09-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
JP5069905B2 (ja) 2003-01-21 2012-11-07 アプテュイト （ウエスト ラファイエット）、エルエルシー 新規な共結晶化
JP4842819B2 (ja) * 2003-09-04 2011-12-21 セフアロン・インコーポレーテツド モダフィニル組成物
JP5017103B2 (ja) * 2004-06-17 2012-09-05 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 薬剤共結晶組成物および関連した使用方法
WO2006049986A1 (en) * 2004-10-28 2006-05-11 Dr. Reddy's Laboratories Ltd. Polymorphic forms of tadalafil
WO2006050458A2 (en) 2004-11-02 2006-05-11 Teva Pharmaceutical Industries, Ltd. Tadalafil crystal forms and processes for preparing them
NZ577502A (en) * 2006-12-28 2012-02-24 Hoffmann La Roche Crystalline forms glyt1
JP6074142B2 (ja) * 2009-02-26 2017-02-01 タール ファーマシューティカルズ，インコーポレイテッド 医薬化合物の結晶化

Also Published As

Publication number Publication date
EP2400848A4 (en) 2012-07-25
US9040535B2 (en) 2015-05-26
US8586587B2 (en) 2013-11-19
EP2400848A1 (en) 2012-01-04
JP2015134774A (ja) 2015-07-27
US20120046297A1 (en) 2012-02-23
JP2012519178A (ja) 2012-08-23
WO2010099323A1 (en) 2010-09-02
US20140100233A1 (en) 2014-04-10

Similar Documents

Publication Publication Date Title
JP2015134774A (ja) 医薬化合物の結晶化
JP5043286B2 (ja) バラシクロビル塩酸塩の結晶型
CN112851666B (zh) 阿哌沙班与槲皮素共晶物及制备方法和其组合物与用途
WO2001080857A9 (en) Zolpidem hemitartrate
AU2001257213A1 (en) Zolpidem hemitartrate
JP6392766B2 (ja) ベンフォチアミン多形体、調製方法およびその使用
CN107056813B (zh) 德罗格韦钠盐的晶型及其制备方法
AU2015330554A1 (en) Crystal form of bisulfate of JAK inhibitor and preparation method therefor
CN101365708A (zh) 1－苯甲酰基－4－[2－[4－甲氧基－7－(3－甲基－1h－1,2,4－三唑－1－基)－1－[(膦酰氧基)甲基]－1h－吡唑并[2,3－c]吡啶－3－基]－1,2－二氧代乙基]－哌嗪的结晶形式
TWI496773B (zh) Ｎ－［２－［［（２，３－二氟苯基）甲基］硫基］－６－｛［（１ｒ，２ｓ）－２，３－二羥基－１－甲基丙基］氧基｝－４－嘧啶基］－１－三亞甲亞胺磺醯胺之新穎結晶型
RU2300529C2 (ru) Кристаллическая натриевая соль парекоксиба
JP2007525538A (ja) バラシクロビル塩酸塩の結晶フォーム（ｆｏｒｍ）
JP5628816B2 (ja) リコフェロンのコリンおよびトロメタミン塩
JP2012521417A (ja) アデフォビルジピボキシルの新規結晶形及びその製造方法
TW201002654A (en) Solid states of aliskiren free base
WO2013023439A1 (zh) 一种吡唑并嘧啶酮化合物的盐、多晶型物及其药物组合物、制备方法和应用
WO2022224269A1 (en) Co-crystals, salts and solid forms of niraparib
CA2407063A1 (en) Solid dispersion with improved absorbability
US20230172854A1 (en) A solid co-amorphous dispersion of valsartan, a method for synthetizing the same and a medical use of the dispersion
WO2025203051A1 (en) Ribociclib succinate form c and process thereof
EP4469052A1 (en) Novel compositions
KR20250140387A (ko) 벤즈이미다졸 유도체 약물의 신규한 공결정 소재 및 그의 제조방법
TW202613137A (zh) 新晶型
TW200526659A (en) New compounds
CN112079835A (zh) 一种5型磷酸二酯酶抑制剂的钾盐晶型b及其制备方法和应用

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140514

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140813

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140916

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150205

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150318

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20150410

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160720

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20161027

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170106

R150 Certificate of patent or registration of utility model

Ref document number: 6074142

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R370 Written measure of declining of transfer procedure

Free format text: JAPANESE INTERMEDIATE CODE: R370

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees